Stay updated with breaking news from Nextcure inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NextCure, Inc. (NASDAQ:NXTC – Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 90,500 shares, a decline of 19.5% from the April 30th total of 112,400 shares. Based on an average trading volume of 287,500 shares, the days-to-cover ratio is […] ....
NextCure, Inc. (NASDAQ:NXTC – Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 90,500 shares, a drop of 19.5% from the April 30th total of 112,400 shares. Based on an average daily volume of 287,500 shares, the […] ....
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
NextCure (NASDAQ:NXTC) Rating Reiterated by Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
NextCure (NASDAQ:NXTC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 422.88% from the company’s previous close. Separately, Needham & […] ....